Breaking News, Collaborations & Alliances

Dragonfly, Merck Partner to Evaluate DF9001 in Combination with Keytruda

Hope to drive potent anti-tumor activity in a broad range of indications.

Author Image

By: Charlie Sternberg

Associate Editor

Dragonfly Therapeutics Inc., a clinical-stage biotechnology company developing novel immunotherapies, has entered a clinical collaboration with Merck to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors expressing EGFR.   Bill Haney, co-founder and CEO of Dragonfly Therapeutics, said, “We are pleased to enter into this agreement with Merck for our ongoing, investiga...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters